Topic:

Clinical Trials

Latest Headlines

Latest Headlines

China green-lights domestic Ebola shot for clinical trials

China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday.

GSK shingles candidate hits its mark in hefty Phase III study

More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.

GlaxoSmithKline scores a PhIII success for marathon shingles vaccine study

GlaxoSmithKline got some good news for its big vaccines group, scoring a pivotal Phase III win for its shingles vaccine HZ/su more than four years after the study was launched.

Tetraphase spikes on a Phase III success for lead antibiotic

Shares of Tetraphase Pharmaceuticals spiked 15% Wednesday afternoon after the biotech said its lead antibiotic hit its primary endpoint in a head-to-head Phase III study, leaving the company on track to file for an approval before the end of next year.

Neovacs blasted after lead therapy flops in PhIIb for rheumatoid arthritis

Paris-based Neovacs got hammered yesterday after the biotech spread the word that its Phase IIb study of an experimental therapeutic vaccine for rheumatoid arthritis flopped.

Amgen tests T-Vec's combo potential in trial with Merck's Keytruda

Amgen's cancer vaccine candidate may be awaiting FDA and EMA approval as a melanoma monotherapy, but like many of its peers, it's also looking to explore its prospect's potential as part of an immunotherapy duo, and now it's kicked off a trial combining its treatment with Merck's anti-PD-1 therapy that should help it do just that.

PaxVax meets primary endpoints in PhIII cholera vaccine trial

Right now, there is no FDA-approved cholera vaccine for U.S. travelers heading to high-risk countries. A California company hopes to change that soon: On Monday, PaxVax said it planned to submit a Biologics License Application for its oral single-dose candidate in mid-2015.

Circassia looks to higher doses to salvage ragweed drug after PhIIb miss

Circassia Pharmaceuticals' pipeline has suffered its first notable post-IPO setback. The British biotech's ragweed allergy drug failed to live up to expectations in a Phase IIb trial, prompting the company to dig deeper into the data in search of a path forward for the candidate.

Merck, NewLink Ebola vaccine trial shows no serious side effects so far

Just days after GlaxoSmithKline and the NIH's National Instite of Allergy and Infectious Diseases announced Phase I success for their investigative Ebola vaccine, Merck and NewLink Genetics have their own positive news to report.

GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI

The race for an Ebola vaccine is ramping up with positive Phase I data from an experimental vaccine made by GlaxoSmithKline and the NIH's National Institute of Allergy and Infectious Diseases. And thanks to those results, larger trials could be on the way soon.